SOHM, Inc., Announces Initial Purchase Order for its new CBD product line.
CHINO HILLS, CA—January 27, 2021 – SOHM, Inc. (Pink Sheets: SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announced today some of the developments with the company and their new product line purchase orders into the US OTC retail, prescription, contract manufacturing, and white label manufacturing and marketing space.
SOHM has received an initial purchase order from its B2B customer for its newly launched CBD Pain Relief Cream in a private label agreement.
This is just the beginning of launching its CBD line of products into major retail stores. SOHM’s customer will be distributing them to various chain stores throughout the United States.
This new purchase order comes from a current customer that has been purchasing products from SOHM since 2017.
Mr. Baron Night, the CEO, said, “SOHM is very pleased to have received this order from this customer that supplies retail and pharmacy networks all across the United States. This represents an annualized commitment once this order is executed and the product is on the shelf of retail stores.
Mr. Night continued saying that the company also anticipates another purchase order for one of its travel size Hand Sanitizer products from the same customer. SOHM’s spokesperson said once the CBD based product line and other product orders are in its pipeline, it will assure that SOHM achieves its target for higher revenue growth in 2021 compared to previous years.
About SOHM, Inc.
SOHM, Inc., is a growing generic pharmaceutical manufacturing and marketing company with a vision “Globalè Prospèro” that tries to build continuous growth. SOHM manufacturing and marketing targets the rapidly growing healthcare segments such as Nutraceuticals, Cosmeceuticals, and other major therapeutic segments. SOHM is headquartered in North America with manufacturing alliances in India as well as has strategic alliances with US manufacturing facilities. Although SOHM’s generic pharmaceuticals are exported globally and were introduced to the USA in early 2013, SOHM continues its focus on distribution to emerging markets in Africa, Latin America, and Southeast Asia.
To know more about SOHM, Inc., visit www.SOHM.com
Safe Harbor Statement:
This news release contains “forward-looking statements”, which are statements that are not purely historical and include any statements regarding beliefs, plans, expectations, or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs, and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations, and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations, or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on for the most recent fiscal year, our quarterly reports uploaded from time-to-time on OTCMarkets.com.
For more information, please contact:
SOHM, Inc.
714-522-6700